DE60032621D1 - Die verwendung von estrogen-verbindungen zur behandlung von osteoporose - Google Patents

Die verwendung von estrogen-verbindungen zur behandlung von osteoporose

Info

Publication number
DE60032621D1
DE60032621D1 DE60032621T DE60032621T DE60032621D1 DE 60032621 D1 DE60032621 D1 DE 60032621D1 DE 60032621 T DE60032621 T DE 60032621T DE 60032621 T DE60032621 T DE 60032621T DE 60032621 D1 DE60032621 D1 DE 60032621D1
Authority
DE
Germany
Prior art keywords
osteoporosis
treatment
estrogen compounds
estrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032621T
Other languages
English (en)
Other versions
DE60032621T2 (de
Inventor
Ulla Timonen
Raija Vaheri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of DE60032621D1 publication Critical patent/DE60032621D1/de
Application granted granted Critical
Publication of DE60032621T2 publication Critical patent/DE60032621T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60032621T 1999-10-15 2000-10-13 Die verwendung von estrogen-verbindungen zur behandlung von osteoporose Expired - Lifetime DE60032621T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15950199P 1999-10-15 1999-10-15
US159501P 1999-10-15
PCT/FI2000/000890 WO2001026640A2 (en) 1999-10-15 2000-10-13 Treatment of osteoporosis

Publications (2)

Publication Number Publication Date
DE60032621D1 true DE60032621D1 (de) 2007-02-08
DE60032621T2 DE60032621T2 (de) 2007-10-04

Family

ID=22572821

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032621T Expired - Lifetime DE60032621T2 (de) 1999-10-15 2000-10-13 Die verwendung von estrogen-verbindungen zur behandlung von osteoporose

Country Status (13)

Country Link
EP (1) EP1223940B1 (de)
JP (1) JP2003511409A (de)
KR (1) KR20020048952A (de)
AR (1) AR034100A1 (de)
AT (1) ATE349215T1 (de)
AU (1) AU778482B2 (de)
CA (1) CA2388237C (de)
CZ (1) CZ20021278A3 (de)
DE (1) DE60032621T2 (de)
HU (1) HUP0203741A3 (de)
MX (1) MXPA02003770A (de)
PL (1) PL354539A1 (de)
WO (1) WO2001026640A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10125391B4 (de) * 2001-05-23 2005-01-27 Siemens Ag Vorrichtung zum Bestücken von Substraten mit elektrischen Bauelementen
IL158871A0 (en) 2001-07-31 2004-05-12 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393539B1 (de) * 1989-04-18 1993-08-04 HENNING BERLIN GmbH CHEMIE- UND PHARMAWERK Orale Zubereitungsform des Östradiolvalerats
EP0461290B1 (de) * 1990-06-14 1994-01-12 HENNING BERLIN GmbH CHEMIE- UND PHARMAWERK Flüssig befüllte Steckkapselpräparate
DE4405591C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution

Also Published As

Publication number Publication date
HUP0203741A2 (hu) 2003-02-28
EP1223940B1 (de) 2006-12-27
EP1223940A2 (de) 2002-07-24
JP2003511409A (ja) 2003-03-25
PL354539A1 (en) 2004-01-26
WO2001026640A2 (en) 2001-04-19
WO2001026640A3 (en) 2001-10-18
CA2388237C (en) 2010-06-01
CZ20021278A3 (cs) 2003-06-18
CA2388237A1 (en) 2001-04-19
KR20020048952A (ko) 2002-06-24
MXPA02003770A (es) 2002-12-13
AU7926300A (en) 2001-04-23
HUP0203741A3 (en) 2004-09-28
AR034100A1 (es) 2004-02-04
AU778482B2 (en) 2004-12-09
ATE349215T1 (de) 2007-01-15
DE60032621T2 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE394103T1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60029033D1 (de) Verfahren zur Behandlung von Tissuepapier
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE60035326D1 (de) Verfahren zur Behandlung von Abwasser
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE69905214T2 (de) Mittel zur Behandlung der Osteoporose
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE69828998D1 (de) Indolderivate verwendbar zur behandlung von u.a. osteoporosis
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition